by Gregg C. Fonarow, Clyde W. Yancy, Nancy M. Albert, Anne B

Slides:

Advertisements

Similar presentations

© 2010, American Heart Association. All rights reserved. Evolving Patterns of Use and Appropriateness of Aldosterone Antagonists in Heart Failure Nancy.

Advertisements

Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology Practices: Primary Results of the Registry to Improve Heart Failure Therapies.

Associations Between Outpatient Heart Failure Process of Care Measures and Mortality Gregg C. Fonarow, Nancy M. Albert, Anne B. Curtis, Mihai Gheorghiade,

Heart Failure: Living with a Hurting Heart. Congestive Heart Failure Heart (or cardiac) failure is the state in which the heart is unable to pump blood.

Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology Practices: Primary Results of the Registry to Improve Heart Failure Therapies.

Subgroup Placebo n/N (%) Serelaxin n/N (%)Favours placeboFavours serelaxin Odds ratio Estimate (95%CI) Interaction P value Total population150/580 (25.9)156/581.

Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical Effectiveness of CRT and ICD Therapy in.

Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effect of Intermittent Atrial Tachyarrhythmia.

Date of download: 6/26/2016 From: Comparative Effectiveness of Cardiac Resynchronization Therapy With an Implantable Cardioverter- Defibrillator Versus.

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Clyde W. Yancy, MD, MSc, MACC, FAHA, FHFSA, Mariell.

Fig ACCF/AHA Guideline for the management of heart failure

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,

Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:

Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for.

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;

Circ Arrhythm Electrophysiol

The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice Jonathan G. Howlett, MD, FRCPC, Michael Chan, MBBS,

Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation Anh L. Bui, MD, Maria.

Chapter 8: Cardiovascular Disease in Patients with ESRD

Volume 1: Chronic Kidney Disease

by Adam J. Singer, Robert H

Forecasting the Impact of Heart Failure in the United States

Atrial Fibrillation and Mortality in Heart FailureClinical Perspective

Evaluation of Left Ventricular Enlargement as a Marker of Early Disease in Familial Dilated CardiomyopathyClinical Perspective by Diane Fatkin, Thomas.

Modest Increase in Peak VO2 Is Related to Better Clinical Outcomes in Chronic Heart Failure PatientsClinical Perspective by Ann M. Swank, John Horton,

Current and future paradigm for prognostication and testing of therapeutics in patients with heart failure using machine learning. Current and future paradigm.

Developed in Collaboration With The American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology,

Diabetes Mellitus and Heart Failure

Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection Derek V. Exner, MD, MPH, David.

Clyde W. Yancy et al. JACC 2017;70:

The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice Jonathan G. Howlett, MD, FRCPC, Michael Chan, MBBS,

Improving Transitions in CKD: Failure Mode

Figure 1 Energy supply–demand matching in health and heart failure

Chapter 4: Cardiovascular Disease in Patients with CKD

José L. Morales et al. JACEP 2017;j.jacep

Frederic Rahbari-Oskoui, MD, MS American Journal of Kidney Diseases

Nancy M. Albert, PhD, Gregg C. Fonarow, MD, William T

Deborah J. Clegg, PhD, Michael Cody, MD, Biff F. Palmer, MD

Eugene Braunwald JCHF 2013;1:1-20

Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology,

Chapter 8: Cardiovascular Disease in Patients with ESRD

David D. Berg et al. JACC 2018;71:

Belinda Gray et al. JCHF 2013;1:

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Fig. 2. Evidence-based medication prescriptions

Nat. Rev. Cardiol. doi: /nrcardio

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016 Murray Epstein, MD, Daniel A. Duprez,

Mahesh Anantha Narayanan et al. JACEP 2017;3:

Ethnic and racial disparities in cardiac resynchronization therapy

Schematic diagram showing as yet unexplored pathophysiological mechanisms in pulmonary arterial hypertension (PAH). Schematic diagram showing as yet unexplored.

Shannon M. Dunlay, MD, MS, Naveen L. Pereira, MD, Sudhir S

Volume 12, Issue 10, Pages (October 2015)

Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.

Emilce Trucco et al. JACEP 2018;j.jacep

Mahesh Anantha Narayanan et al. JACEP 2017;j.jacep

Rami Doukky et al. JCHF 2016;4:24-35

Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.

Ali Ahmed, MD, MPH, Michael W. Rich, MD, Michael Zile, MD, Paul W

Ali Ahmed, MD, Gregg C. Fonarow, MD, Yan Zhang, MS, MSPH, Paul W

Comparative Superiority of ACE Inhibitors Over Angiotensin Receptor Blockers for People With CKD: Does It Matter? Dimitris Mavridis, PhD American Journal.

Figure 1 Diagnostic algorithm for cardiac transthyretin amyloidosis

Saadia Sherazi et al. JACEP 2015;1:74-80

Results of comparisons of treatments in the network.

Jeffrey Senfield et al. JACEP 2017;3:

Schematic of the interaction between the renin-angiotensin-aldosterone system (RAAS) system and the natriuretic peptides and how the RAAS modulators and.

β-Blocker Use for the Stages of Heart Failure

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Flow diagram of the recommended pharmacological management of heart failure adapted from the European Society of Cardiology guidelines Flow diagram.

Presentation transcript:

Heart Failure Care in the Outpatient Cardiology Practice SettingCLINICAL PERSPECTIVE by Gregg C. Fonarow, Clyde W. Yancy, Nancy M. Albert, Anne B. Curtis, Wendy Gattis Stough, Mihai Gheorghiade, J. Thomas Heywood, Mark L. McBride, Mandeep R. Mehra, Christopher M. O'Connor, Dwight Reynolds, and Mary Norine Walsh Circ Heart Fail Volume 1(2):98-106 July 1, 2008 Copyright © American Heart Association, Inc. All rights reserved.

Figure 1. IMPROVE HF care metrics at baseline. Figure 1. IMPROVE HF care metrics at baseline. Aldosterone antagonist, cardiac resynchronization therapy (CRT), or implantable cardioverter defibrillators (ICD) therapy care metrics are not American College of Cardiology/American Heart Association (ACC/AHA) outpatient heart failure (HF) performance measures. Gregg C. Fonarow et al. Circ Heart Fail. 2008;1:98-106 Copyright © American Heart Association, Inc. All rights reserved.

Figure 2. Frequency distribution of care metric rates by practice. Figure 2. Frequency distribution of care metric rates by practice. Box plots represent median, 10th, and 90th percentiles, and lines for minimum and maximum conformity rates across practices. Gregg C. Fonarow et al. Circ Heart Fail. 2008;1:98-106 Copyright © American Heart Association, Inc. All rights reserved.

Figure 3. Frequency distribution of care metric rates by practice for (A) angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB), (B) β-blocker, (C) aldosterone antagonist, (D) anticoagulation therapy, (E) cardiac resynchronization therapy (CRT) (devices with defibrillation [CRT-Ds]/CRT with pacemaker), (F) implantable cardioverter defibrillators (ICD)/CRT-D, and (G) heart failure (HF) education. Figure 3. Frequency distribution of care metric rates by practice for (A) angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB), (B) β-blocker, (C) aldosterone antagonist, (D) anticoagulation therapy, (E) cardiac resynchronization therapy (CRT) (devices with defibrillation [CRT-Ds]/CRT with pacemaker), (F) implantable cardioverter defibrillators (ICD)/CRT-D, and (G) heart failure (HF) education. Gregg C. Fonarow et al. Circ Heart Fail. 2008;1:98-106 Copyright © American Heart Association, Inc. All rights reserved.